Evidence map›Paper›PMID 42665741›Full record

ReviewJournal of cardiovascular translational research2026

The Trajectory of Epigenetic Chromatin Remodeling in Cardiometabolic Disease and its Therapeutic Implications.

Mirjana Macvanin, Aleksandra Klisic

Abstract readReview
PubMed Publisher
In one paragraph

Review in Journal of cardiovascular translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Mirjana MacvaninInstitute of Chemistry, Technology and Metallurgy, Center for Chemistry, National Institute of the Republic of Serbia, University of Belgrade, Belgrade, Serbia.
Aleksandra KlisicUniversity of Montenegro-Faculty of Medicine, Podgorica, Montenegro. aleksandranklisic@gmail.com.ORCID 0000-0001-7870-0996

Funding

Ministarstvo Prosvete, Nauke i Tehnološkog Razvoja 451-03-33/2026-03/200026Ministry of Education, Science, and Innovation, Montenegro 01-082/22-1681/3
6 · The paper itself

Abstract

The pathogenesis and progression of cardiometabolic diseases (CMD) are intricately linked to epigenetic regulation mediated by chromatin remodeling. Modifications to histones, such as post-translational acetylation and methylation, along with DNA methylation, alter chromatin structure and accessibility, resulting in transient or irreversible alterations in gene expression without accompanying changes in the DNA sequence. Herein, we outline the trajectory of epigenetic chromatin remodeling across various tissues, focusing on the liver-heart axis and the crosstalk between various epigenetic mechanisms in CMD pathogenesis and progression. We provide a list of drugs that target crucial epigenetic enzymes for CMD treatment. Furthermore, we propose possible future directions for the development of effective therapies targeting the crosstalk interaction points of epigenetic mechanisms involved in CMD.

Indexed as

Cardiovascular DiseasesChromatin Assembly and DisassemblyEpigenesis, GeneticAcetylationAnimalsCardiovascular AgentsDNA MethylationHistonesHumansMolecular Targeted TherapyProtein Processing, Post-TranslationalCardiovascular AgentsHistonesCardiometabolic diseaseCrotonylationDNA methylationEpigeneticsHistone acetylationHistone methylationLactylationLliver-heart axisSuccinylationTherapeutic interventions

Identifiers

PMID42665741

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.